What are the possible side effects of Farxiga? [Select All That Apply]:
 
a. Dehydration
b. Ketoacidosis
c. Urinary tract infections
d. Vaginal yeast infections
e. Balanitis

What are the possible side effects of Farxiga? [Select All That Apply]:
 
a. Dehydration
b. Ketoacidosis
c. Urinary tract infections
d. Vaginal yeast infections
e. Balanitis

Answer: (a,b,c,d,e)
 
The active ingredient found in Farxiga is Dapagliflozin (Farxiga).  
 
Farxiga may cause serious side effects including:
1. Dehydration
2. Ketoacidosis
3. Serious urinary tract infections (UTI)
4. Low blood sugar (hypoglycemia)
5. Bacterial infections under the skin of the genitals and areas around them
6. Vaginal yeast infections
7. Yeast infection of skin around the penis (balanitis) in men.

The most common side effects of Dapagliflozin (Farxiga) include yeast infections of the vagina or penis, and changes in urination, including urgent need to urinate more often, in larger amounts, or at night.

Farxiga is indicated to [Select All That Apply]:
 
a. improve blood sugar control along with diet and exercise in adults with type 2 diabetes.
b. reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.
c. reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
d. reduce the risk of diabetic ketoacidosis in adults with type 1 diabetes.

Farxiga is indicated to [Select All That Apply]:
 
a. improve blood sugar control along with diet and exercise in adults with type 2 diabetes.
b. reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.
c. reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
d. reduce the risk of diabetic ketoacidosis in adults with type 1 diabetes.

Answer: (a,b,c)
 
The active ingredient found in Farxiga is Dapagliflozin (Farxiga).  Farxiga is indicated to:
 
1. improve blood sugar control along with diet and exercise in adults with type 2 diabetes.
2. reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.
3. reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
 
Farxiga should not be used to treat people with type 1 diabetes or diabetic ketoacidosis (increased ketones in your blood or urine).
 
To improve glycemic control, the recommended starting dose of Farxiga is 5 mg orally once daily, taken in the morning, with or without food. In patients tolerating Farxiga 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily.

Farxiga is:

a. 5HT-1 receptor Antagonist
b. Alpha-2 inhibitor
c. Renin inhibitor
d. SGLT2 inhibitor
e. SSRI

Farxiga is:

a. 5HT-1 receptor Antagonist
b. Alpha-2 inhibitor
c. Renin inhibitor
d. SGLT2 inhibitor
e. SSRI

The active ingredient found in Farxiga is Dapagliflozin (Farxiga). It is the first sodium glucose co-transporter 2 (SGLT2) inhibitor approved by the US FDA. It is available as tablets (5mg and 10mg).

Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Dapagliflozin (Farxiga) is an inhibitor of SGLT2. By inhibiting SGLT2, Dapagliflozin (Farxiga) reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Dapagliflozin (Farxiga) also reduces sodium reabsorption and increase the delivery of sodium to distal tubule. This may influence several physiological functions including, but not limited to, lowering both pre-and afterload of the heart and downregulation of sympathetic activity.

Dapagliflozin (Farxiga) is a prescription medicine used to:

1. improve blood sugar control along with diet and exercise in adults with type 2 diabetes

2. reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and known cardiovascular disease or multiple cardiovascular risk factors

3. reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (when the heart is weak and cannot pump enough blood to the rest of your body)

Dapagliflozin (Farxiga) should not be used to treat people with type 1 diabetes or diabetic ketoacidosis (increased ketones in your blood or urine).

Usual Adult Dose for Diabetes Type 2:

a. To improve glycemic control (can be taken with or without food):

1. Initial dose: 5 mg orally once a day
2. May increase to 10 mg orally once a day for additional glycemic control if lower dose has been tolerated
3. Maximum dose: 10 mg/day

b. To reduce the risk of hospitalization for heart failure: 10 mg orally once a day.

Dehydration, ketoacidosis, UTI infection, hypoglycemia and vaginal yeast infection are reported side effects of the drug.

Try our Naplex QBank. www.pharmacyexam.com